CFM
LXRX icon

Catalyst Funds Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Catalyst Funds Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-207,900
Closed -$324K – 788
2026
Q1 		$324K Buy
207,900
+167,600
+416% +$244K 0.05% 333
2025
Q4 		$46.3K Hold
40,300
– – 0.01% 325
2025
Q3 		$54.4K Sell
40,300
-13,400
-25% -$15.2K 0.01% 475
2025
Q2 		$50.8K Buy
+53,700
New +$34.8K 0.01% 371

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Catalyst Funds Management's LXRX Position: Q2 2026 in Review

Catalyst Funds Management sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2026, closing a stake of 207,900 shares — an estimated $324K sold.

Catalyst Funds Management first reported a position in LXRX in Q2 2025 and held it in 4 quarters. The position peaked at $324K in Q1 2026. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Catalyst Funds Management reported no remaining Lexicon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Catalyst Funds Management sold 207,900 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $324K.
  • Catalyst Funds Management first reported a position in Lexicon Pharmaceuticals in Q2 2025 and held it in 4 quarters.
  • Catalyst Funds Management's Lexicon Pharmaceuticals position peaked at $324K in Q1 2026.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.